Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in all laboratories of pathology. This method is generally used for diagnostic purposes, but several studies have investigated the sensitivity and specificity of different immunohistochemical antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical examination of the works comparing the consistency of IHC expression and conventional molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed.
Introduction
More than half of non-small cell lung cancer (NSCLC), in particular adenocarcinoma histologic type, show genetic alterations involving oncogenic drivers leading to aberrant activation of tyrosine kinases acting as molecular targets for selective inhibitors. 1, 2 The presence of these genetic alterations is the unique most important finding in predicting effectiveness of specific targeted therapies. 3 Most important, patients with adenocarcinomas harbouring epidermal growth factor receptor (EGFR) mutations or Anaplastic Lymphoma Kinase (ALK) and ROS1 rearrangements have a significant disease-free survival when compared with conventional chemotherapy. [4] [5] [6] [7] [8] [9] [10] This revolutionary therapeutic approach in patients with NSCLC generally requires a drug specific "companion diagnostic" test to select patients with tumors harboring genetic alterations. 11 Of note, some "companion diagnostics" have been approved differently in various countries. [12] [13] [14] In brief, approximately 10% to 40% of lung adenocarcinomas (mainly depending on ethnicity with highest frequency in Asiatic patients) harbor a EGFR mutation and about 90% of these mutations occur in exons 19 (E746-A750 deletion and other short in-frame variants of this deletions in exon 19 ) and 21 (leucine to arginine substitution at amino acid 858, L858R). 1, 2 Less common mutations predicting a minor clinical response to EGFR tyrosine kinase inhibitors (TKI) occur in exons 18 and 20. [15] [16] [17] Overall, EGFR mutations are the best predictors of efficacy when adopting selective TKIs, namely gefitinib, erlotinib and afatinib. [4] [5] [6] Several PCR-based DNA extractive methods are available and accepted to detect EGFR mutations, although there is a wide range in terms of sensitivities among various methodologies, significantly leading to quite different results. 13, 14, 18, 19 About 5-7% of lung adenocarcinomas harbor a rearrangement of ALK gene, particularly through an intrachromosomal inversion with EML4-ALK gene and other genes, then leading to a fusion product associated with ALK protein overexpression. 12 Clinical features, (e.g., young age, non/light-smoking habit, adenocarcinoma with cribriform/signet ring cell pattern) cannot reliably identify patients with ALK-positive tumors. 20 Fluorescence in-situ hybridization (FISH) using breakapart probe is currently considered the gold standard for detection of ALK rearrangement, since clinical trials with the dual MET and ALK-inhibitor crizotinib are based on ALK FISH detection. [7] [8] [9] More recently, the rearrangement of ROS1 gene has been identified in a small subset (about 1-2%) of lung adenocarcinomas. 21 Detection of ROS1 rearrangement in the recent clinical trial by Shaw et al. 10 was performed using a break apart probe with FISH assay.
Other promising gene alterations involving BRAF, HER2, RET and c-MET seem to predict novel therapeutic scenarios in NSCLC. 2, 22 Although immunohistochemistry (IHC) is the main ancillary technique in pathology labs and it has been largely demonstrated that some antibodies against EGFR, ALK and ROS1 can indirectly detect the presence of gene alterations with high specificity and fair-to-high sensitivity, this technique is not validated to directly select patients undergoing specific targeted therapies in NSCLC, as instead happen in breast and gastric cancer with HER2 detection. 23 Although generally poorly-appreciated in the molecular biology community, IHC is a rapid, cheap and well-known assay that does not require huge tumor cell content and perform quite well even in degraded tissue (e.g., decalcified bone tissue) or cytology samples ( Table 1) .
In the present review, we aimed at summarizing the characteristics and the performance rate in terms of sensitivity and specificity of the antibodies acting as possible surrogates to predictive molecular tests, also discussing the future landscape in which IHC could be adequately adopted as screening as well as confirmatory test to detect predictive biomarkers in routine clinical practice.
EGFR mutations
The finding of an activating EGFR mutation in NSCLC is the best single predictor of efficacy using selective tyrosine kinase inhibitors (TKI), while total EGFR expression at immunohistochemistry and EGFR FISH assay did not demonstrate to be reliable predicting biomarkers. 3 cases, when using low-sensitive DNA extractive techniques.
As summarized in Table 2 , the sensitivity of these antibodies is very variable (ranging from 30% to 100% with a mean value between 60% and 70%), mainly depending on the cut-off scoring system to quote immunoreactivity, while the specificity is excellent (overall >90%). Of course, these mutant-specific antibodies do not stain tumors harboring EGFR mutations different from E746-A750del and L858R.
Basically, the sensitivity of mutant-specific antibodies to detect all EGFR mutations range from about 40% to 60%. Thus, EGFR mutant-specific antibodies cannot replace conventional DNA sequencing molecular methods in detecting this predictive biomarker. Nevertheless, these antibodies should represent a valid adjunct to molecular techniques when specimens contain a low cellularity or poorly-preserved tumor cells. In fact, tumor cell showing consistent expression (score 2+/3+) for these antibodies firmly indicate the presence of the relevant EGFR mutation (Figures 1 and 2 ).
ALK rearrangement
In 2007, Soda et al. 55 Since ALK protein is not expressed in normal adult lung tissue, IHC appears a robust alternative method in identifying lung cancers harbouring ALK rearrangement. Provided that IHC is not expensive and of rapid execution, it has the great advantage to be the most used ancillary technique in all laboratories of pathology. The main problem is that the cellular content of ALK protein in ALK rearranged NSCLC tumor cells is much lower that that observed in ALK-lymphomas. 61 Then, the concentration of the primary antibody against ALK should be increased and the positive signal needs improvement by using appropriate detection and visualization kits to increase the inter-observer reproducibility. Despite different protocols and primary antibody clones, the results comparing ALK detection by IHC and FISH are quite good, if not excellent ( Table   3) . In particular, it is important to underline that consistent positivity (score of intensity 2+ and 3+)
with ALK at IHC is almost always associated with a positive FISH test and, most important, all negative cases at IHC are basically negative at FISH analysis ( Figure 3 ). While it is quite exceptional to have ALK IHC negative and FISH positive cases, about 1-2% of IHC positive and FISH negative cases have been well-documented and these cases do respond to ALK inhibitor.
101-104
The main concerns about the use of IHC as screening tool in detecting ALK-positive lung tumors rely on the fact that: 1. clinical trials with crizotinib refer only to positive patients with FISH test; 2.
the sensitivity in detecting ALK tumors may depend on different clones and detection systems; 3.
the lack of complete interobserver reproducibility among pathologists when using 4-tier scoring systems and low sensitivity antibody clones. The limited sensitivity reported in preliminary reports is overridden by more recent works that highlight a almost complete correlation between IHC and FISH methods, particularly when using clones 5A4 and D5F3 coupled to an adequate detection kit. 85, 105, 106, 108 Needless to say that since lung cancer generally has a low expression of ALK protein at a cytoplasmic and/or membrane level when compared with ALK lymphomas, and weak staining (score 1+) may be associated with a ALKrearranged tumor, all these cases require a confirmatory determination using FISH assay.
Finally, some novel ALK fusion gene (e.g., KIF5B-ALK) were identified by IHC in cases originally tested negative at FISH analysis. 68 Application of adequate external controls in each bath, the use of standardized protocols incorporating the correct choice of antibody clone and detection kit as well as the participation to external quality control assurance programs should always considered to ensure rigorous immunohistochemical results in routine practice, providing an effective integration of IHC with FISH testing. 76, 106, 108 Selinger et al. 70 recently reported 100% specificity between IHC and FISH testing 594 resected NSCLCs with either ALK1, 5A4, D5F3 clones. IHC also evidenced 6, 11 and 6 ALK + cases using ALK1
(5 with 1+ and 1 with 2+ score), 5A4 (10 with 1+, 1 with 2+ score) and D5F3 (3 with 1+, 2 with 2+ and 1 with 1+ score), respectively.
Minca et al. 76 demonstrated 100% sensitivity and specificity of D5F3 clone using the Ventana While all used ALK clones show an excellent specificity, the clone ALK1 is characterized by a moderate sensitivity ranging from 60% to 90% with a relatively low intensity of staining. When using a less sensitive clone, the results could be improved by "high-sensitivity" pathologists carefully noticing all staining shadows ( Figure 5) . As a rule, the less sensitive clone is adopted, the more sensitive should be the pathologist examining ALK test on IHC.
By contrast, sensitivity and specificity of studies with clone 5A4 are quite consistent ranging from 95% to 100%. Studies employing clones ALK1 and 5A4 used a four-tier scoring system (from 0-negative to 1+-weak, 2+-moderate, 3+-strong intensity staining), somehow complicating the interobserver reproducibility. The binary system adopted when using the high-sensitivity D5F3-based kit proposed by Ventana clearly facilitate ALK determination by IHC even in the hands of less expert pathologists. 105, 106, 108 Reviewing the last 153 consecutive screened lung adenocarcinomas (unpublished observations), the sensitivity and specificity of the clone ALK1 adopting the OptiView detection kit and the automated immunostainer BenchMark XT (Ventana Medical Instruments, Tucson, AZ, USA) are 100% and 96%, respectively. Eighteen ALK-positive cases (11.8%) were identified at IHC and 12 at FISH assay (7.8%). All FISH positive cases showed moderate-to-strong expression at IHC level, while among the 6 discordant cases 5 revealed a weak intensity (score 1+) and 1 with a moderate (2+ score) intensity showed gene amplification at FISH test. In addition, other 27 randomly selected ALK negative cases at IHC were entirely negative also with FISH. Of note, 3 out of 12 ALKpositive cases had a concomitant EGFR (1 case) or KRAS (2 cases) mutation using MALDI-TOF methodology, according to other experiences. 24, 86 Practically speaking, IHC is a likely accessible, low-cost, rapid and widely informative technique to detect ALK status in NSCLC. High-sensitivity IHC protocols (particularly when using the clone D5F3
and OptiView amplification kit) are quite consistent when compared to FISH results and should be introduced as validated screening test to detect ALK positive patients requiring a confirmatory FISH test in a limited NSCLC population.
ROS1
ROS1 is a receptor tyrosine kinase involved in tumor cancerogenesis of different tumors. 
114-116
Recent studies have confirmed the validity of the clone D4D6 to detect ROS1 rearrangement when IHC assay was compared to FISH test ( Table 4) . [117] [118] [119] [120] Basically, all ROS1 FISH-positive cases showed a consistent (moderate to strong and diffuse) expression of ROS1 protein. (score 2+/3+) in more than 50% of tumor cells, the specificity of ROS1 clone D4D6 becomes quite consistent (>95%).
117-120
While different previous studies have demonstrated the validity of IHC method in terms of specificity and sensitivity to identify ROS1-rearranged NSCLC, a recent work by Cha et al. 119 highlighted some false positive tumors in ever-smokers. By contrast, Boyle et al. 111 recently demonstrated that ROS1 IHC assay has an absolute sensitivity and specificity when compared with FISH and reverse transcriptase polymerase chain reaction (RT-PCR) using an optimized scoring system (H-score >100) (Figure 6 ).
Taking into account all previous data, IHC screening with ROS1 clone D4D6 seems to be reasonably robust to be adopted as a practical, rapid and cost-effective screening tool in detecting ROS1-rearranged NSCLC, then limiting the number of cases to undergo confirmatory FISH assay.
Others (BRAF mutations, RET rearrangement, HER2 mutations, c-MET expression)
BRAF mutations occur in 1-3% of patients with lung adenocarcinoma and occur more commonly in current and former smokers. 
V600E
. 121, 122 However, in NSCLC a wide range of other missense mutations (non-V600E) have been detected in exons 11 and 15. 121, 122 The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in other extrapulmonary malignancies.
121,122
The reported BRAF mutations by Paik et al. 121 were V600E (50%), G469A (39%), and D594G (11%).
In the work by Marchetti et al. 122 56.8% mutations were V600E, and 43.2% were non-V600E. All non-V600E mutations were found in smokers.
The V600E mutation-specific antibody (clone VE1) has been recently developed. 123 This clone perfectly match with V600E BRAF mutations in melanoma and papillary thyroid carcinoma.
There is a unique study by Ilie et al. 124 demonstrating VE1 expression in 19 out of 21 (90%) BRAF V600E mutated adenocarcinomas. As expected, this mutant-specific antibody failed to stain all other 10 non-V600E mutations identified in the work.
HER2/EGFR-2 mutations characterize a subset of NSCLC (about 3%), particularly in non-smoking
younger patients with adenocarcinoma subtype. 125 To date, most of HER2 mutations detected in NSCLC were in-frame insertions of exon 20 with duplication of amino acids YVMA at codon 775 (A775_G776insYVMA). 125, 126 However, neither FISH test nor IHC consistently matched with HER2 mutations, then appearing inconsistent tools in predicting HER2 mutated adenocarcinomas. Given the similarity of mutational events, it could be that a mutant-specific antibody will be developed in the next future to identify HER2 mutations in lung adenocarcinoma at IHC level.
The RET (rearranged during transfection) proto-oncogene is located at 10q11.2 and encodes a receptor tyrosine kinase. 127 The RET protein is lacking in lung tissue and RET rearrangement has been recently identified in NSCLC. [128] [129] [130] [131] [132] [133] A subset (1-2%) of lung adenocarcinomas harbour fusion of the KIF5B (kinesin family
member 5B) gene to the RET (rearranged during transfection) gene or other RET gene fusions, namely
TRIM33-RET, NCOA4-RET, and CCDC6-RET.
A clinical response has been demonstrated using RET inhibitors in RET fusion-positive lung adenocarcinomas. 134, 135 In a recent study, Lee et al. 133 showed that 16% (15 out of 94) of EGFR/KRAS/ALK triple-negative lung adenocarcinomas harboured RET rearrangement. In contrast to previous studies, 129, 132 the authors demonstrated moderate-to-strong immunoreactivity for RET at IHC (clone 134100, Abcam) in all 15 RET fusion-positive cases 100% of sensitivity), while a focal staining was observed also in 10 out of 79 (12%) RET fusion-negative cases (89% of specificity).
Adenocarcinoma of the lung harboring RET-rearrangement seem to have a peculiar morphology with crobroform pattern, lymphangitic spread and psammoma bodies. 
